Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy

International Journal of Chronic Obstructive Pulmonary Disease ◽

10.2147/copd.s265037 ◽

2020 ◽

Vol Volume 15 ◽

pp. 2715-2725

Author(s):

Chad Moretz ◽

Beth Hahn ◽

John White ◽

Alyssa Goolsby Hunter ◽

Breanna Essoi ◽

...

Keyword(s):

Fluticasone Propionate ◽

Symptom Burden ◽

Medicare Advantage ◽

Gold Classification

Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4300 ◽

2020 ◽

Author(s):

C. Moretz ◽

B. Hahn ◽

J. White ◽

A. Goolsby Hunter ◽

B. Essoi ◽

...

Keyword(s):

Fluticasone Propionate ◽

Symptom Burden ◽

Medicare Advantage

Prediction Of Asthma Symptom Burden In Subjects Dispensed Low/Moderate Dose Fluticasone Propionate/Salmeterol (FSC) or Moderate/High Dose Fluticasone Propionate (FP) in Subjects Without History of ICS Use

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2009.12.279 ◽

2010 ◽

Vol 125 (2) ◽

pp. AB71

Author(s):

R.H. Stanford ◽

A. Riedel ◽

J. Burke ◽

B. Borah ◽

M. Kulakodlu

Keyword(s):

Fluticasone Propionate ◽

Asthma Symptom ◽

Symptom Burden ◽

High Dose ◽

Moderate Dose ◽

History Of

Dutch Researchers Find Fluticasone Propionate Is Not Effective in Infants

Pediatric News ◽

10.1016/s0031-398x(05)70248-4 ◽

2005 ◽

Vol 39 (5) ◽

pp. 35

Author(s):

Kate Johnson

Keyword(s):

Fluticasone Propionate

Marketing on Hold for Medicare Advantage Plans

Skin & Allergy News ◽

10.1016/s0037-6337(07)70671-x ◽

2007 ◽

Vol 38 (8) ◽

pp. 60

Author(s):

MARY ELLEN SCHNEIDER

Keyword(s):

Medicare Advantage

A comparison of the clinical efficacy and safety of intranasal fluticasone propionate and antihistamines in the treatment of rhinitis

Allergy ◽

10.1034/j.1398-9995.2000.055suppl62012.x ◽

2000 ◽

Vol 55 (suppl 62) ◽

pp. 12-14 ◽

Cited By ~ 12

Author(s):

A. Foresi

Keyword(s):

Fluticasone Propionate ◽

Clinical Efficacy ◽

Efficacy And Safety

Hospitals spend less for patients in Medicare Advantage than for patients in fee-for-service Medicare

PsycEXTRA Dataset ◽

10.1037/e504352010-032 ◽

2009 ◽

Keyword(s):

Fee For Service ◽

Medicare Advantage

The impact of a CBT treatment for mood disorders on symptom burden reports in HIV-infected substance users with depression

PsycEXTRA Dataset ◽

10.1037/e546872013-189 ◽

2013 ◽

Author(s):

Janna Gordon ◽

Conall O'Cleirigh ◽

Jonathan Lerner ◽

Steven A. Safren

Keyword(s):

Mood Disorders ◽

Symptom Burden ◽

Substance Users ◽

The Impact

Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study

Yearbook of Medicine ◽

10.1016/s0084-3873(08)70163-9 ◽

2007 ◽

Vol 2007 ◽

pp. 243-244

Author(s):

J.R. Maurer

Keyword(s):

Lung Disease ◽

Obstructive Lung Disease ◽

Atherosclerosis Risk In Communities ◽

Gold Classification ◽

Atherosclerosis Risk ◽

Global Initiative ◽

Aric Study

Congress Eyes Medicare Advantage Pay for Fee Fix—Again

Clinical Psychiatry News ◽

10.1016/s0270-6644(08)70279-0 ◽

2008 ◽

Vol 36 (4) ◽

pp. 68

Author(s):

ALICIA AULT

Keyword(s):

Medicare Advantage

CMS Proposes Medicare Advantage Changes

Clinical Psychiatry News ◽

10.1016/s0270-6644(07)70484-8 ◽

2007 ◽

Vol 35 (7) ◽

pp. 60

Author(s):

MARY ELLEN SCHNEIDER

Keyword(s):

Medicare Advantage